Results 11 to 20 of about 1,551 (70)

Changes in neutrophil-to-lymphocyte ratio in patients with polycythemia vera treated with ruxolitinib reflect JAK2 variant allele frequency

Haematologica
Not available.
Paola Guglielmelli, Chiara Paoli, Giulia Borgi, Lorenzo Fagiolo, Sara Bianchini, Giuseppe Gaetano Loscocco, Francesca Gesullo, Fernanda di Vaio, Cecilia Matteoli, Fabiana Pancani, Sofia Danesi, Simona Pestelli, Tiziano Barbui, Alessandro M. Vannucchi   +13 more
doaj   +1 more source

Molecular biology of Philadelphia-negative myeloproliferative neoplasms

Revista Brasileira de Hematologia e Hemoterapia, 2012
Myeloproliferative neoplasms are clonal diseases of hematopoietic stem cells characterized by myeloid hyperplasia and increased risk of developing acute myeloid leukemia.
Paulo Vidal Campregher, Fábio Pires de Souza Santos, Guilherme Fleury Perini, Nelson Hamerschlak   +3 more
doaj   +1 more source

One thousand patients with essential thrombocythemia: the Florence-CRIMM experience

Blood Cancer Journal
We describe 1000 patients with essential thrombocythemia seen at the Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Florence, Italy, between 1980 and 2023: median age 59 years (18–95), females 65%, JAK2/CALR/MPL-mutated 66%/19%/4%
Giuseppe G. Loscocco, Francesca Gesullo, Giulio Capecchi, Alessandro Atanasio, Chiara Maccari, Francesco Mannelli, Alessandro M. Vannucchi, Paola Guglielmelli   +7 more
doaj   +1 more source

Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib

Haematologica
Not available.
Giacomo Coltro, Giulio Capecchi, Margherita Maffioli, Francesco Mannelli, Barbara Mora, Alessandro Atanasio, Alessandra Iurlo, Chiara Maccari, Mirko Farina, Elena Nacca, Marianna Caramella, Leonardo Signori, Miriam Borella, Lorenza Bertù, Maria Esposito, Paola Guglielmelli, Francesco Passamonti, Alessandro Maria Vannucchi   +17 more
doaj   +1 more source

JAK2V617F mutation in a patient with B-cell chronic lymphocytic leukemia and prefibrotic primary myelofibrosis [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2015
Introduction. Secondary malignancies, particularly solid tumors, are common in patients with chronic lymphocytic leukemia (CLL), but association of myeloproliferative neoplasms and chronic lymphocytic leukemia in the same patient is very rare ...
Ristić Slobodan, Radojković Milica, Kostić Tatjana, Spasovski Vesna, Pavlović Sonja, Čemerikić-Martinović Vesna   +5 more
doaj   +1 more source

Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis

Frontiers in Oncology, 2020
Numerous studies have documented ultrastructural abnormalities in malignant megakaryocytes from bone marrow (BM) of myelofibrosis patients but the morphology of these cells in spleen, an important extramedullary site in this disease, was not investigated
Maria Zingariello, Vittorio Rosti, Alessandro M. Vannucchi, Paola Guglielmelli, Maria Mazzarini, Giovanni Barosi, Maria Luisa Genova, Anna Rita Migliaccio, Anna Rita Migliaccio   +8 more
doaj   +1 more source

JAK2 rs10974944 is associated with both V617F‐positive and negative myeloproliferative neoplasms in a Vietnamese population: A potential genetic marker

Molecular Genetics & Genomic Medicine, 2022
The JAK2 gene encodes for a non‐receptor tyrosine kinase that plays a key role in the JAK/STAT signaling transfer pathway. Genetic polymorphisms of this gene have been indicated to be associated with myeloproliferative neoplasm‐associated thrombosis in ...
Nguyen Thy Ngoc, Bui Bich Hau, Nguyen Ba Vuong, Nguyen Thi Xuan   +3 more
doaj   +1 more source

Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting

Haematologica
Not available.
Gaia Ciolli, Matteo Piccini, Francesco Mannelli, Giacomo Gianfaldoni, Barbara Scappini, Laura Fasano, Francesca Crupi, Elisa Quinti, Andrea Pasquini, Jessica Caroprese, Giada Rotunno, Fabiana Pancani, Leonardo Signori, Chiara Maccari, Fiorenza I. Vanderwert, Paola Guglielmelli, Alessandro M. Vannucchi   +16 more
doaj   +1 more source

JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms

Advances in Hematology, 2012
JAK2 is a tyrosine kinase gene that plays an essential role in the development of normal haematopoiesis. Hyperactivation of JAK2 occurs in myeloproliferative neoplasms by different mechanisms.
Mar Bellido, Peter A. W. te Boekhorst
doaj   +1 more source

Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation

Hematology, Transfusion and Cell Therapy, 2018
Background: Cytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms.
Maira da Costa Cacemiro, Juçara Gastaldi Cominal, Raquel Tognon, Natalia de Souza Nunes, Belinda Pinto Simões, Lorena Lôbo de Figueiredo-Pontes, Luiz Fernando Bazzo Catto, Fabíola Traina, Elizabeth Xisto Souto, Fabiana Albani Zambuzi, Fabiani Gai Frantz, Fabíola Attié de Castro   +11 more
doaj   +1 more source